A recent report from Marcelo Barone of Combate has revealed that UFC fighter Rogerio Bontorin is in the mediation process for a drug test collected by the U.S. Anti-Doping Agency last year that found a violation of their policy.
Bontorin reportedly tested positive for hydrochlorothiazide, a diuretic that is not allowed under USADA’s testing rules. The test was collected in May as part of the program’s “out of competition” testing program done on fighters that aren’t set to compete at a specific date.
Bontorin is currently in the process of attempting to prove that a tainted supplement caused the test result, per a follow-up report from Guilherme Cruz of MMA Fighting. Proving this could limit a two-year suspension by a significant amount.
USADA has not publicly commented on Bontorin’s ongoing case. The organization only publicly addresses cases once they have been completely resolved.
Bontorin has been part of the USADA testing program since 2018 and has been tested 20 times, per their database. He has competed five times in the UFC, attaining three wins through five appearances.
He last appeared in May, where he defeated Matt Schnell to snap a two-fight skid.